SCHEMBL5729015

SCHEMBL5729015

CC(Oc1ccc(C(=O)c2c(-c3ccc(O)cc3)noc2-c2ccc(O)cc2)c(C(F)(F)F)c1)C1CCCCN1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.33
ADORA1 P30542 5/20 0.33
KCNH2 Q12809 4/20 0.33
CYP3A4 P08684 3/20 0.33
ADORA3 P0DMS8 2/20 0.33
ADORA2B P29275 1/20 0.33
CYP2C19 P33261 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NR1I2 O75469 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
HTR1A P08908 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
CNR1 P21554 1/20 0.33
GLRA1 P23415 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6307449 0.88 PTGS1 (0.35) CYP2C19TP53CYP2D6SLC6A2SLC6A4
SCHEMBL5729286 0.86 PTGS1 (0.34) TP53SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL5729312 0.84 PTGS1 (0.34) TSHRSLC6A2SLC6A4SLC6A3MEN1
SCHEMBL5731066 0.83 PTGS1 (0.34) KDM4ELMNATP53HTTMEN1
SCHEMBL5729633 0.83 SLC6A2 (0.37) CYP3A4CYP2C19KDM4ELMNACYP2D6
SCHEMBL5729513 0.83 SLC6A2 (0.37) CYP3A4CYP2C19KDM4ELMNACYP2D6
SCHEMBL5729019 0.82 CHEK2 (0.40) KCNH2CYP3A4CYP2C19LMNACYP1A2
SCHEMBL5729587 0.82 ALDH1A1 (0.38) CYP2C19KDM4ELMNACYP2D6SLC6A2
Hydrochloric Acid SCHEMBL6311267 0.81 ALDH1A1 (0.38) CYP2C19LMNACYP2D6SLC6A2SLC6A4
SCHEMBL5729700 0.81 PTGS1 (0.35) LMNATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102755-B1 SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORP (US) 2006-01-04 EP disclosed
US-6869969-B2 Estrogen receptor modulators CHIRON CORPORATION (US) 2005-03-22 US disclosed
US-6743815-B2 OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE CHIRON CORPORATION 2004-06-01 US disclosed
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors CHIRON CORPORATION 2004-05-27 US disclosed
US-20030065012-A1 Estrogen receptor modulators CHIRON CORPORATION (US) 2003-04-03 US disclosed
US-6387920-B2 ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE CHIRON CORPORATION 2002-05-14 US disclosed
US-20010036956-A1 Estrogen receptor modulators HUEBNER VERENA D (US) 2001-11-01 US disclosed
US-6262098-B1 ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036956-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 ADORA2A 128/4885ADORA1 172/4885KCNH2 4397/4885
US-20030065012-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 ADORA2A 128/4885ADORA1 172/4885KCNH2 4397/4885
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors ESR2, GPER1, ESR1 ADORA2A 169/4885ADORA1 333/4885KCNH2 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.